Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 3
2017 5
2018 8
2019 3
2020 5
2021 5
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

29 results
Results by year
Filters applied: . Clear all
Page 1
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators. Pfisterer J, et al. Among authors: el balat a. Lancet Oncol. 2020 May;21(5):699-709. doi: 10.1016/S1470-2045(20)30142-X. Epub 2020 Apr 16. Lancet Oncol. 2020. PMID: 32305099 Clinical Trial.
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Harter P, Mouret-Reynier MA, Pignata S, Cropet C, González-Martín A, Bogner G, Fujiwara K, Vergote I, Colombo N, Nøttrup TJ, Floquet A, El-Balat A, Scambia G, Guerra Alia EM, Fabbro M, Schmalfeldt B, Hardy-Bessard AC, Runnebaum I, Pujade-Lauraine E, Ray-Coquard I. Harter P, et al. Among authors: el balat a. Gynecol Oncol. 2022 Feb;164(2):254-264. doi: 10.1016/j.ygyno.2021.12.016. Epub 2021 Dec 22. Gynecol Oncol. 2022. PMID: 34952708 Free article. Clinical Trial.
Claudin-1 expression in cervical cancer.
Hoellen F, Waldmann A, Banz-Jansen C, Holtrich U, Karn T, Oberländer M, Habermann JK, Hörmann M, Köster F, Ribbat-Idel J, Thill M, Rody A, El-Balat A, Hanker L. Hoellen F, et al. Among authors: el balat a. Mol Clin Oncol. 2017 Nov;7(5):880-884. doi: 10.3892/mco.2017.1391. Epub 2017 Aug 25. Mol Clin Oncol. 2017. PMID: 29181184 Free PMC article.
Histotype-specific analysis of acid ceramidase expression in ovarian cancer.
El-Balat A, Karn T, Holtrich U, Becker S, Kommoss S, Győrffy B, Anglesio MS, Huntsman DG, Drosos Z, Rody A, Gevensleben H, Hanker LC. El-Balat A, et al. Virchows Arch. 2020 Jun;476(6):855-862. doi: 10.1007/s00428-019-02728-0. Epub 2020 Jan 2. Virchows Arch. 2020. PMID: 31897818
Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancer.
Hanker LC, El-Balat A, Drosos Z, Kommoss S, Karn T, Holtrich U, Gitas G, Graeser-Mayer M, Anglesio M, Huntsman D, Rody A, Gevensleben H, Hoellen F. Hanker LC, et al. Among authors: el balat a. J Cancer Res Clin Oncol. 2021 May;147(5):1421-1430. doi: 10.1007/s00432-021-03558-x. Epub 2021 Mar 3. J Cancer Res Clin Oncol. 2021. PMID: 33660008 Free PMC article.
IMP3 Expression in Borderline Tumors of the Ovary.
El-Balat A, Sänger N, Karn T, Becker S, Holtrich U, Muallem Z, Arsenic R. El-Balat A, et al. Anticancer Res. 2017 Feb;37(2):583-588. doi: 10.21873/anticanres.11351. Anticancer Res. 2017. PMID: 28179304
What is the evidence for lymphadenectomy in presumed early ovarian cancer?
Schmalfeldt B, Brambs C, Burges A, El-Balat A, Emons G, Fink D, Fotopoulou C, Gropp-Meier M, Hanker LC, Harter P, Hasenburg A, Hauptmann S, Hilpert F, Kimmig R, Kommoss S, Kurzeder C, Mahner S, Marmé F, Mayr D, Meier W, Meinhold-Heerlein I, Mustea A, Ortmann O, Oskay-Özcelik G, Pfisterer J, Pölcher M, Runnebaum IB, Schröder W, Tanner B, Wagner U, Wimberger P, Sehouli J. Schmalfeldt B, et al. Among authors: el balat a. Arch Gynecol Obstet. 2019 Jan;299(1):1-5. doi: 10.1007/s00404-018-4945-8. Arch Gynecol Obstet. 2019. PMID: 30374648 No abstract available.
29 results